A start-up company led by top international researchers in gut microbiology and immunity
Ibiome Biology Co., Ltd, Ltd. is a biotechnology company focusing on the innovative research and development of human gut microbiota, and a start-up company led by top international researchers in gut microbiology and immunity. The core R&D team consists of scientists from top international universities such as Yale University, Harvard Medical School, and University of Science and Technology of China.
The company's core business is the development of intestinal bacteria drugs, and the immunotherapy of human intestinal microorganisms. Develop clinical treatment solutions including metabolic diseases, anti-tumor, inflammatory bowel disease, autoimmune diseases, etc., marking the development of the largest domestic and international immunomodulatory strains development enterprise.
|
|
Experimental Area - Molecular Laboratory
|
|
Experimental area - process room
|
|
Experimental area - bacterial isolation room
|
|
Experimental Area - Molecular Laboratory
|
|
Experimental Area - Molecular Laboratory
|
|
Experimental Area - Microbial Library
|
|
Recreation area
|
|
Experimental area - intercellular
|
|
Experimental area - clean area
|
|
Experimental area - clean area
|
|
Experimental area - process room
|
|
Experimental area - process room
|
|
Experimental area - bacterial isolation room
|
|
Open office area
|
|
Reception area
|
|
Recreation area
|
|
Park environment
|
|
Park environment
Working environment
|
|
Professional R&D team
The company's core R&D team is composed of many scientists from top international universities such as Yale University, Harvard Medical School, University of Science and Technology of China, Chinese Academy of Sciences, etc., and has a solid working foundation in the research of intestinal microbes, host immunity, and intestinal microbe-related diseases. , research results have been published in top international journals for many times.
Cell (2021), Nature Reviews Gastroenterology & Hepatology, (2021), PNAS (2021), Nature Immunology (2019), Nature (2017a, 2017b), Science (2015), Nat Comm (2015).
|
|
Yale University
|
|
Harvard University
|
|
University of Science and Technology of China
|
|
Chinese Academy of Sciences
Richard Flavell, PhD
—
Professor, Yale University
Immunology
IBD
Immune-Microbiome
WengJianping, Ph.D.
—
Chinese Academy of Sciences Clinical
Hospital Dean
Endocrine metabolism
disease
Eran Elinav, MD,PhD
—
Professor, Weizmannx Institute
Microbiome
Personized nutrition
Microbiota
ZhaoShen Li, Ph.D.
—
Chinese Academy of Engineering
academician
Changhai Hospital Digestion
Director of Internal Medicine
Noah Palm, PhD
—
Assistant Professor,
Yale University
Microbial metabolites
IgA sequencing
Hong Zhang, Ph.D.
—
Peking University First Hospital Kidney
Deputy Director of Internal Medicine
IgA nephropathy
Strong consultant team
Gut immunity
Gut microbiome
Cell , 2021
Nat Cell Bio , In Revision
PNAS , 2021
Nature , 2017a
Nat Med , 2012
Nat Comm , 2015
J Exp Med , 2010
J Immunol , 2010
Cell , 2019
Science , 2016
Nat Immunol, 2012
Nature Biomedical Engineering , In Revision
Nature Reviews Gastroenterology & Hepatology , 2021
Protein & Cell , 2020
Nature Immunology , 2019
Nature , 2017b
Science , 2015
CMI , 2019
Elife , 2018
Immunity , 2015
Immunity , 2014
Red , (co)first or corresponding author ; Blue , coauthor
Address: 16th Floor, Building E, Intelligent Equipment Technology Park, No. 3963, Susong Road, Economic and Technological Development Zone, Hefei City
Tel: 0551-63813386
Email: hr@ibiome.com.cn